Gal Bitan

Professor-in-Residence, Neurology, University of California Los Angeles

310-206 2082

Gal Bitan got his PhD in organic chemistry from the Hebrew University of Jerusalem, Israel. During his postdoc at Brigham and Women's Hospital/Harvard Medical School, Boston, MA, Dr. Bitan worked on pathologic self-assembly of amyloid ß-protein (Aß) and made fundamental contributions to the study of early events in the pathologic cascades that cause Alzheimer's disease, including the discovery of one of the earliest oligomers in the assembly cascade, the paranucleus. In 2004, Dr. Bitan joined UCLA where he is currently a Professor of Neurology. His research program combines basic and translational research focused on neurodegenerative proteinopathies, including Alzheimer's disease, other tauopathies, Parkinson's disease, and atypical parkinsonian disorders. The Bitan group has discovered small molecules called "molecular tweezers" that are broad-spectrum inhibitors of abnormal protein oligomerization and aggregation. A lead compound, CLR01, was shown to ameliorate disease phenotype and reduce toxic protein aggregates in pre-clinical models of Alzheimer's disease, Parkinson's disease, multiple system atrophy, amyotrophic lateral sclerosis, transthyretin amyloidosis, and desmin-related cardiomyopathy. In a different line of research, the group has been developing biomarkers in blood products and CNS-originating extracellular vesicles isolated from the blood, and has shown that such biomarkers can distinguish between Parkinson's disease and multiple system atrophy with high sensitivity and specificity using a simple blood test. In a related study, several biomarkers have been discovered for the lysosomal disease, Sanfilippo syndrome. The Bitan group is also the first to discover exophers in mammalian neurons. Exophers are new cellular compartments/extracellular vesicles described to date only in C. elegans, which are thought to participate in non-cell-autonomous clearance of dysfunctional organelles and protein aggregates, in addition to other, currently unknown roles in neurophysiology.

Interests

extracellular vesicles, Exophers, Biomarkers, Amyloid, Parkinson's disease, Proteinopathy, Drug development, Alzheimer's disease, Prion-like seeding, exosomes

Education and Training

Brigham and Women's Hospital/Harvard Medical SchoolPostdoc03/2003Protein folding and assembly
Beth Israel Deaconess Medical Center/Harvard Medical SchoolPostdoc09/1999Structural Biology and protein Biochemistry
The Hebrew University of JerusalemPhD04/1996Organic Chemistry

Awards and Honors

  • Turken Award for Alzheimer’s Disease Research, UCLA, 2005.
  • Invited Plenary Lecture Asilomar Conference on Neurodegenerative Diseases, American Society for Mass Spectrometry, 2021.
  • Invited Keynote Speaker of Annual Symposium, The MSA Coalition, 2021.
  • Inaugural Undergraduate Faculty Mentor Award, UCLA, 2018.

Publications

  1. Polgreen LE, Chen AH, Pak Y, Luzzi A, Morales Garval A, Acevedo J, Bitan G, Iacovino M, O'Neill C, Eisengart JB. Anakinra in Sanfilippo syndrome: a phase 1/2 trial.. Nature medicine, 2024.
  2. Sexton CE, Bitan G, Bowles KR, Brys M, Buée L, Maina MB, Clelland CD, Cohen AD, Crary JF, Dage JL, Diaz K, Frost B, Gan L, Goate AM, Golbe LI, Hansson O, Karch CM, Kolb HC, La Joie R, Lee SE, Matallana D, Miller BL, Onyike CU, Quiroz YT, Rexach JE, Rohrer JD, Rommel A, Sadri-Vakili G, Schindler SE, Schneider JA, Sperling RA, Teunissen CE, Weninger SC, Worley SL, Zheng H, Carrillo MC. Novel avenues of tau research.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024.
  3. Hong M, Bitan G. Recent advances and future therapy development for Alzheimer's disease and related disorders.. Neural regeneration research, 2023.
  4. Lantz C, Lopez J, Goring AK, Zenaidee MA, Biggs K, Whitelegge JP, Ogorzalek Loo RR, Klärner FG, Schrader T, Bitan G, Loo JA. Characterization of Molecular Tweezer Binding on α-Synuclein with Native Top-Down Mass Spectrometry and Ion Mobility-Mass Spectrometry Reveals a Mechanism for Aggregation Inhibition.. Journal of the American Society for Mass Spectrometry, 2023.
  5. Taha HB, Chawla E, Bitan G. IM-MS and ECD-MS/MS Provide Insight into Modulation of Amyloid Proteins Self-Assembly by Peptides and Small Molecules.. Journal of the American Society for Mass Spectrometry, 2023.
  6. Dutta S, Hornung S, Taha HB, Bitan G. Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges.. Acta neuropathologica, 2023.
  7. Taha HB, Hornung S, Dutta S, Fenwick L, Lahgui O, Howe K, Elabed N, Del Rosario I, Wong DY, Duarte Folle A, Markovic D, Palma JA, Kang UJ, Alcalay RN, Sklerov M, Kaufmann H, Fogel BL, Bronstein JM, Ritz B, Bitan G. Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson's disease and multiple system atrophy.. Translational neurodegeneration, 2023.
  8. Dutta S, Hornung S, Taha HB, Biggs K, Siddique I, Chamoun LM, Shahpasand-Kroner H, Lantz C, Herrera-Vaquero M, Stefanova N, Loo JA, Bitan G. Development of a Novel Electrochemiluminescence ELISA for Quantification of α-Synuclein Phosphorylated at Ser129 in Biological Samples.. ACS chemical neuroscience, 2023.
  9. Dutta S, Sklerov M, Teunissen CE, Bitan G. Editorial: Trends in biomarkers for neurodegenerative diseases: Current research and future perspectives.. Frontiers in aging neuroscience, 2023.
  10. Maina KN, Smet-Nocca C, Bitan G. Using FRET-Based Biosensor Cells to Study the Seeding Activity of Tau and α-Synuclein.. Methods in molecular biology (Clifton, N.J.), 2023.
  11. Shahpasand-Kroner H, Siddique I, Malik R, Linares GR, Ivanova MI, Ichida J, Weil T, Münch J, Sanchez-Garcia E, Klärner FG, Schrader T, Bitan G. Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications.. Pharmacological reviews, 2022.
  12. Monaco A, Maffia V, Sorrentino NC, Sambri I, Ezhova Y, Giuliano T, Cacace V, Nusco E, De Risi M, De Leonibus E, Schrader T, Klärner FG, Bitan G, Fraldi A. The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease.. Molecular therapy : the journal of the American Society of Gene Therapy, 2022.
  13. Taha HB, Kearney B, Bitan G. A minute fraction of α-synuclein in extracellular vesicles may be a major contributor to α-synuclein spreading following autophagy inhibition.. Frontiers in molecular neuroscience, 2022.
  14. Dutta S, Nimse SB, Van Keuren-Jensen K, Bitan G. Editorial: Exosomes: Message in a vesicle.. Frontiers in pharmacology, 2022.
  15. Palma JA, Martinez J, Millar Vernetti P, Ma T, Perez MA, Zhong J, Qian Y, Dutta S, Maina KN, Siddique I, Bitan G, Ades-Aron B, Shepherd TM, Kang UJ, Kaufmann H. mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.. Movement disorders : official journal of the Movement Disorder Society, 2022.
  16. Shahpasand-Kroner H, Portillo J, Lantz C, Seidler PM, Sarafian N, Loo JA, Bitan G. Three-repeat and four-repeat tau isoforms form different oligomers.. Protein science : a publication of the Protein Society, 2022.
  17. Murakami K, Izuo N, Bitan G. Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases.. The Journal of biological chemistry, 2021.
  18. Li Z, Siddique I, Hadrovic I, Kirupakaran A, Li J, Zhang Y, Klärner FG, Schrader T, Bitan G. Lysine-selective molecular tweezers are cell penetrant and concentrate in lysosomes.. Communications biology, 2021.
  19. Dutta S, Hornung S, Kruayatidee A, Maina KN, Del Rosario I, Paul KC, Wong DY, Duarte Folle A, Markovic D, Palma JA, Serrano GE, Adler CH, Perlman SL, Poon WW, Kang UJ, Alcalay RN, Sklerov M, Gylys KH, Kaufmann H, Fogel BL, Bronstein JM, Ritz B, Bitan G. α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy.. Acta neuropathologica, 2021.
  20. Malishev R, Salinas N, Gibson J, Eden AB, Mieres-Perez J, Ruiz-Blanco YB, Malka O, Kolusheva S, Klärner FG, Schrader T, Sanchez-Garcia E, Wang C, Landau M, Bitan G, Jelinek R. Inhibition of Staphylococcus aureus biofilm-forming functional amyloid by molecular tweezers.. Cell chemical biology, 2021.
  21. Di J, Siddique I, Li Z, Malki G, Hornung S, Dutta S, Hurst I, Ishaaya E, Wang A, Tu S, Boghos A, Ericsson I, Klärner FG, Schrader T, Bitan G. The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice.. Alzheimer's research & therapy, 2021.
  22. Bengoa-Vergniory N, Faggiani E, Ramos-Gonzalez P, Kirkiz E, Connor-Robson N, Brown LV, Siddique I, Li Z, Vingill S, Cioroch M, Cavaliere F, Threlfell S, Roberts B, Schrader T, Klärner FG, Cragg S, Dehay B, Bitan G, Matute C, Bezard E, Wade-Martins R. CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease.. Nature communications, 2020.
  23. Weil T, Groß R, Röcker A, Bravo-Rodriguez K, Heid C, Sowislok A, Le MH, Erwin N, Dwivedi M, Bart SM, Bates P, Wettstein L, Müller JA, Harms M, Sparrer K, Ruiz-Blanco YB, Stürzel CM, von Einem J, Lippold S, Read C, Walther P, Hebel M, Kreppel F, Klärner FG, Bitan G, Ehrmann M, Weil T, Winter R, Schrader T, Shorter J, Sanchez-Garcia E, Münch J. Supramolecular Mechanism of Viral Envelope Disruption by Molecular Tweezers.. Journal of the American Chemical Society, 2020.
  24. Malik R, Corrales C, Linsenmeier M, Alalami H, Sepanj N, Bitan G. Examination of SOD1 aggregation modulators and their effect on SOD1 enzymatic activity as a proxy for potential toxicity.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020.
  25. Mason AJ, Hurst I, Malik R, Siddique I, Solomonov I, Sagi I, Klärner FG, Schrader T, Bitan G. Different Inhibitors of Aβ42-Induced Toxicity Have Distinct Metal-Ion Dependency.. ACS chemical neuroscience, 2020.
  26. Bitan G. The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question-are polyphenols a viable therapeutic option against proteinopathies?. Annals of translational medicine, 2020.
  27. Hornung S, Dutta S, Bitan G. CNS-Derived Blood Exosomes as a Promising Source of Biomarkers: Opportunities and Challenges.. Frontiers in molecular neuroscience, 2020.
  28. Monaco A, Maffia V, Sorrentino NC, Sambri I, Ezhova Y, Giuliano T, Cacace V, Nusco E, De Risi M, De Leonibus E, Schrader T, Klärner FG, Bitan G, Fraldi A. The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease.. Molecular therapy : the journal of the American Society of Gene Therapy, 2020.
  29. Shin WS, Di J, Cao Q, Li B, Seidler PM, Murray KA, Bitan G, Jiang L. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation.. Alzheimer's research & therapy, 2019.
  30. Hadrovic I, Rebmann P, Klärner FG, Bitan G, Schrader T. Molecular Lysine Tweezers Counteract Aberrant Protein Aggregation.. Frontiers in chemistry, 2019.
  31. Hayden EY, Putman J, Nunez S, Shin WS, Oberoi M, Charreton M, Dutta S, Li Z, Komuro Y, Joy MT, Bitan G, MacKenzie-Graham A, Jiang L, Hinman JD. Ischemic axonal injury up-regulates MARK4 in cortical neurons and primes tau phosphorylation and aggregation.. Acta neuropathologica communications, 2019.
  32. Bitan G. Disease-modifying therapy for proteinopathies: Can the exception become the rule?. Progress in molecular biology and translational science, 2019.
  33. Herrera-Vaquero M, Bouquio D, Kallab M, Biggs K, Nair G, Ochoa J, Heras-Garvin A, Heid C, Hadrovic I, Poewe W, Wenning GK, Klärner FG, Schrader T, Bitan G, Stefanova N. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy.. Biochimica et biophysica acta. Molecular basis of disease, 2019.
  34. Despres C, Di J, Cantrelle FX, Li Z, Huvent I, Chambraud B, Zhao J, Chen J, Chen S, Lippens G, Zhang F, Linhardt R, Wang C, Klärner FG, Schrader T, Landrieu I, Bitan G, Smet-Nocca C. Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors.. ACS chemical biology, 2019.
  35. Yan Z, Dutta S, Liu Z, Yu X, Mesgarzadeh N, Ji F, Bitan G, Xie YH. A Label-Free Platform for Identification of Exosomes from Different Sources.. ACS sensors, 2019.
  36. Malik R, Meng H, Wongkongkathep P, Corrales CI, Sepanj N, Atlasi RS, Klärner FG, Schrader T, Spencer MJ, Loo JA, Wiedau M, Bitan G. The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS.. The Journal of biological chemistry, 2019.
  37. Atlasi RS, Malik R, Corrales CI, Tzeplaeff L, Whitelegge JP, Cashman NR, Bitan G. Investigation of Anti-SOD1 Antibodies Yields New Structural Insight into SOD1 Misfolding and Surprising Behavior of the Antibodies Themselves.. ACS chemical biology, 2018.
  38. Nshanian M, Lantz C, Wongkongkathep P, Schrader T, Klärner FG, Blümke A, Despres C, Ehrmann M, Smet-Nocca C, Bitan G, Loo JA. Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator.. Journal of the American Society for Mass Spectrometry, 2018.
  39. Röcker AE, Müller JA, Dietzel E, Harms M, Krüger F, Heid C, Sowislok A, Riber CF, Kupke A, Lippold S, von Einem J, Beer J, Knöll B, Becker S, Schmidt-Chanasit J, Otto M, Vapalahti O, Zelikin AN, Bitan G, Schrader T, Münch J. The molecular tweezer CLR01 inhibits Ebola and Zika virus infection.. Antiviral research, 2018.
  40. Hayden EY, Conovaloff JL, Mason A, Bitan G, Teplow DB. Preparation of Pure Populations of Amyloid β-Protein Oligomers of Defined Size.. Methods in molecular biology (Clifton, N.J.), 2018.
  41. Malik R, Di J, Nair G, Attar A, Taylor K, Teng E, Klärner FG, Schrader T, Bitan G. Using Molecular Tweezers to Remodel Abnormal Protein Self-Assembly and Inhibit the Toxicity of Amyloidogenic Proteins.. Methods in molecular biology (Clifton, N.J.), 2018.
  42. Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.. Neurology, 2017.
  43. Richter F, Subramaniam SR, Magen I, Lee P, Hayes J, Attar A, Zhu C, Franich NR, Bove N, De La Rosa K, Kwong J, Klärner FG, Schrader T, Chesselet MF, Bitan G. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2017.
  44. Xu N, Bitan G, Schrader T, Klärner FG, Osinska H, Robbins J. Inhibition of Mutant αB Crystallin-Induced Protein Aggregation by a Molecular Tweezer.. Journal of the American Heart Association, 2017.
  45. Vöpel T, Bravo-Rodriguez K, Mittal S, Vachharajani S, Gnutt D, Sharma A, Steinhof A, Fatoba O, Ellrichmann G, Nshanian M, Heid C, Loo JA, Klärner FG, Schrader T, Bitan G, Wanker EE, Ebbinghaus S, Sanchez-Garcia E. Inhibition of Huntingtin Exon-1 Aggregation by the Molecular Tweezer CLR01.. Journal of the American Chemical Society, 2017.
  46. Daloglu MU, Ray A, Gorocs Z, Xiong M, Malik R, Bitan G, McLeod E, Ozcan A. Computational On-Chip Imaging of Nanoparticles and Biomolecules using Ultraviolet Light.. Scientific reports, 2017.
  47. Hayden EY, Conovaloff JL, Mason A, Bitan G, Teplow DB. Preparation of pure populations of covalently stabilized amyloid β-protein oligomers of specific sizes.. Analytical biochemistry, 2016.
  48. Schrader T, Bitan G, Klärner FG. Molecular tweezers for lysine and arginine - powerful inhibitors of pathologic protein aggregation.. Chemical communications (Cambridge, England), 2016.
  49. Li H, Rahimi F, Bitan G. Modulation of Amyloid β-Protein (Aβ) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting Aβ Toxicity.. ACS chemical neuroscience, 2016.
  50. Lulla A, Barnhill L, Bitan G, Ivanova MI, Nguyen B, O'Donnell K, Stahl MC, Yamashiro C, Klärner FG, Schrader T, Sagasti A, Bronstein JM. Neurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos.. Environmental health perspectives, 2016.
  51. Fogerson SM, van Brummen AJ, Busch DJ, Allen SR, Roychaudhuri R, Banks SM, Klärner FG, Schrader T, Bitan G, Morgan JR. Reducing synuclein accumulation improves neuronal survival after spinal cord injury.. Experimental neurology, 2016.
  52. Roychaudhuri R, Zheng X, Lomakin A, Maiti P, Condron MM, Benedek GB, Bitan G, Bowers MT, Teplow DB. Role of Species-Specific Primary Structure Differences in Aβ42 Assembly and Neurotoxicity.. ACS chemical neuroscience, 2015.
  53. Zheng X, Wu C, Liu D, Li H, Bitan G, Shea JE, Bowers MT. Mechanism of C-Terminal Fragments of Amyloid β-Protein as Aβ Inhibitors: Do C-Terminal Interactions Play a Key Role in Their Inhibitory Activity?. The journal of physical chemistry. B, 2015.
  54. Malishev R, Nandi S, Kolusheva S, Levi-Kalisman Y, Klärner FG, Schrader T, Bitan G, Jelinek R. Toxicity inhibitors protect lipid membranes from disruption by Aβ42.. ACS chemical neuroscience, 2015.
  55. Lump E, Castellano LM, Meier C, Seeliger J, Erwin N, Sperlich B, Stürzel CM, Usmani S, Hammond RM, von Einem J, Gerold G, Kreppel F, Bravo-Rodriguez K, Pietschmann T, Holmes VM, Palesch D, Zirafi O, Weissman D, Sowislok A, Wettig B, Heid C, Kirchhoff F, Weil T, Klärner FG, Schrader T, Bitan G, Sanchez-Garcia E, Winter R, Shorter J, Münch J. A molecular tweezer antagonizes seminal amyloids and HIV infection.. eLife, 2015.
  56. Herzog G, Shmueli MD, Levy L, Engel L, Gazit E, Klärner FG, Schrader T, Bitan G, Segal D. The Lys-Specific Molecular Tweezer, CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.. Biochemistry, 2015.
  57. Lopes DH, Attar A, Nair G, Hayden EY, Du Z, McDaniel K, Dutt S, Bravo-Rodriguez K, Mittal S, Klärner FG, Wang C, Sanchez-Garcia E, Schrader T, Bitan G. Molecular tweezers inhibit islet amyloid polypeptide assembly and toxicity by a new mechanism.. ACS chemical biology, 2015.
  58. Zheng X, Liu D, Klärner FG, Schrader T, Bitan G, Bowers MT. Amyloid β-protein assembly: The effect of molecular tweezers CLR01 and CLR03.. The journal of physical chemistry. B, 2015.
  59. Aronovich D, Bitan G, Bartal G. Exact modeling of cylindrical metal-dielectric multilayers beyond the effective medium approximation.. Optics letters, 2014.
  60. Attar A, Chan WT, Klärner FG, Schrader T, Bitan G. Safety and pharmacological characterization of the molecular tweezer CLR01 - a broad-spectrum inhibitor of amyloid proteins' toxicity.. BMC pharmacology & toxicology, 2014.
  61. Ferreira N, Pereira-Henriques A, Attar A, Klärner FG, Schrader T, Bitan G, Gales L, Saraiva MJ, Almeida MR. Molecular tweezers targeting transthyretin amyloidosis.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2014.
  62. Acharya S, Safaie BM, Wongkongkathep P, Ivanova MI, Attar A, Klärner FG, Schrader T, Loo JA, Bitan G, Lapidus LJ. Molecular basis for preventing α-synuclein aggregation by a molecular tweezer.. The Journal of biological chemistry, 2014.
  63. Attar A, Bitan G. Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models.. Current pharmaceutical design, 2014.
  64. Attar A, Liu T, Chan WT, Hayes J, Nejad M, Lei K, Bitan G. A shortened Barnes maze protocol reveals memory deficits at 4-months of age in the triple-transgenic mouse model of Alzheimer's disease.. PloS one, 2013.
  65. Connors CR, Rosenman DJ, Lopes DH, Mittal S, Bitan G, Sorci M, Belfort G, Garcia A, Wang C. Tranilast binds to aβ monomers and promotes aβ fibrillation.. Biochemistry, 2013.
  66. Attar A, Ripoli C, Riccardi E, Maiti P, Li Puma DD, Liu T, Hayes J, Jones MR, Lichti-Kaiser K, Yang F, Gale GD, Tseng CH, Tan M, Xie CW, Straudinger JL, Klärner FG, Schrader T, Frautschy SA, Grassi C, Bitan G. Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers.. Brain : a journal of neurology, 2012.
  67. Ripoli C, Piacentini R, Riccardi E, Leone L, Li Puma DD, Bitan G, Grassi C. Effects of different amyloid β-protein analogues on synaptic function.. Neurobiology of aging, 2012.
  68. Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Elashoff D, Pratico D, Moskovitz J, Bitan G. Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations.. Dementia and geriatric cognitive disorders, 2012.
  69. Solomonov I, Korkotian E, Born B, Feldman Y, Bitler A, Rahimi F, Li H, Bitan G, Sagi I. Zn2+-Aβ40 complexes form metastable quasi-spherical oligomers that are cytotoxic to cultured hippocampal neurons.. The Journal of biological chemistry, 2012.
  70. Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, Lakshmanan R, Ivanova MI, Loo JA, Klärner FG, Schrader T, Stahl M, Bitan G, Bronstein JM. A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2012.
  71. Sinha S, Lopes DH, Bitan G. A key role for lysine residues in amyloid β-protein folding, assembly, and toxicity.. ACS chemical neuroscience, 2012.
  72. Novick PA, Lopes DH, Branson KM, Esteras-Chopo A, Graef IA, Bitan G, Pande VS. Design of β-amyloid aggregation inhibitors from a predicted structural motif.. Journal of medicinal chemistry, 2012.
  73. Sinha S, Du Z, Maiti P, Klärner FG, Schrader T, Wang C, Bitan G. Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01.. ACS chemical neuroscience, 2012.
  74. Liu T, Bitan G. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.. ChemMedChem, 2012.
  75. Li H, Zemel R, Lopes DH, Monien BH, Bitan G. A two-step strategy for structure-activity relationship studies of N-methylated aβ42 C-terminal fragments as aβ42 toxicity inhibitors.. ChemMedChem, 2012.
  76. Lopes DH, Sinha S, Rosensweig C, Bitan G. Application of photochemical cross-linking to the study of oligomerization of amyloidogenic proteins.. Methods in molecular biology (Clifton, N.J.), 2012.
  77. Rosensweig C, Ono K, Murakami K, Lowenstein DK, Bitan G, Teplow DB. Preparation of stable amyloid β-protein oligomers of defined assembly order.. Methods in molecular biology (Clifton, N.J.), 2012.
  78. Gessel MM, Wu C, Li H, Bitan G, Shea JE, Bowers MT. Aβ(39-42) modulates Aβ oligomerization but not fibril formation.. Biochemistry, 2011.
  79. Li H, Du Z, Lopes DH, Fradinger EA, Wang C, Bitan G. C-terminal tetrapeptides inhibit Aβ42-induced neurotoxicity primarily through specific interaction at the N-terminus of Aβ42.. Journal of medicinal chemistry, 2011.
  80. Moskovitz J, Maiti P, Lopes DH, Oien DB, Attar A, Liu T, Mittal S, Hayes J, Bitan G. Induction of methionine-sulfoxide reductases protects neurons from amyloid β-protein insults in vitro and in vivo.. Biochemistry, 2011.
  81. Sinha S, Lopes DH, Du Z, Pang ES, Shanmugam A, Lomakin A, Talbiersky P, Tennstaedt A, McDaniel K, Bakshi R, Kuo PY, Ehrmann M, Benedek GB, Loo JA, Klärner FG, Schrader T, Wang C, Bitan G. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins.. Journal of the American Chemical Society, 2011.
  82. Urbanc B, Betnel M, Cruz L, Li H, Fradinger EA, Monien BH, Bitan G. Structural basis for Aβ1–42 toxicity inhibition by Aβ C-terminal fragments: discrete molecular dynamics study.. Journal of molecular biology, 2011.
  83. Hochdörffer K, März-Berberich J, Nagel-Steger L, Epple M, Meyer-Zaika W, Horn AH, Sticht H, Sinha S, Bitan G, Schrader T. Rational design of β-sheet ligands against Aβ42-induced toxicity.. Journal of the American Chemical Society, 2011.
  84. Maiti P, Piacentini R, Ripoli C, Grassi C, Bitan G. Surprising toxicity and assembly behaviour of amyloid β-protein oxidized to sulfone.. The Biochemical journal, 2011.
  85. Li H, Monien BH, Lomakin A, Zemel R, Fradinger EA, Tan M, Spring SM, Urbanc B, Xie CW, Benedek GB, Bitan G. Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragments.. Biochemistry, 2010.
  86. Rahimi F, Bitan G. Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.. Journal of visualized experiments : JoVE, 2010.
  87. Urbanc B, Betnel M, Cruz L, Bitan G, Teplow DB. Elucidation of amyloid beta-protein oligomerization mechanisms: discrete molecular dynamics study.. Journal of the American Chemical Society, 2010.
  88. Maiti P, Lomakin A, Benedek GB, Bitan G. Despite its role in assembly, methionine 35 is not necessary for amyloid beta-protein toxicity.. Journal of neurochemistry, 2010.
  89. Li H, Monien BH, Fradinger EA, Urbanc B, Bitan G. Biophysical characterization of Abeta42 C-terminal fragments: inhibitors of Abeta42 neurotoxicity.. Biochemistry, 2010.
  90. Rahimi F, Murakami K, Summers JL, Chen CH, Bitan G. RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity.. PloS one, 2009.
  91. Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea JE, Ruotolo BT, Robinson CV, Bowers MT. Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease.. Nature chemistry, 2009.
  92. Maji SK, Ogorzalek Loo RR, Inayathullah M, Spring SM, Vollers SS, Condron MM, Bitan G, Loo JA, Teplow DB. Amino acid position-specific contributions to amyloid beta-protein oligomerization.. The Journal of biological chemistry, 2009.
  93. Wu C, Murray MM, Bernstein SL, Condron MM, Bitan G, Shea JE, Bowers MT. The structure of Abeta42 C-terminal fragments probed by a combined experimental and theoretical study.. Journal of molecular biology, 2009.
  94. Rahimi F, Maiti P, Bitan G. Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides.. Journal of visualized experiments : JoVE, 2009.
  95. Fradinger EA, Monien BH, Urbanc B, Lomakin A, Tan M, Li H, Spring SM, Condron MM, Cruz L, Xie CW, Benedek GB, Bitan G. C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity.. Proceedings of the National Academy of Sciences of the United States of America, 2008.
  96. Rahimi F, Shanmugam A, Bitan G. Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders.. Current Alzheimer research, 2008.
  97. Condron MM, Monien BH, Bitan G. Synthesis and Purification of Highly Hydrophobic Peptides Derived from the C-Terminus of Amyloid β-Protein.. The open biotechnology journal, 2008.
  98. Yun S, Urbanc B, Cruz L, Bitan G, Teplow DB, Stanley HE. Role of electrostatic interactions in amyloid beta-protein (A beta) oligomer formation: a discrete molecular dynamics study.. Biophysical journal, 2007.
  99. Monien BH, Apostolova LG, Bitan G. Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?. Expert review of neurotherapeutics, 2006.
  100. Teplow DB, Lazo ND, Bitan G, Bernstein S, Wyttenbach T, Bowers MT, Baumketner A, Shea JE, Urbanc B, Cruz L, Borreguero J, Stanley HE. Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approach.. Accounts of chemical research, 2006.
  101. Seabrook TJ, Thomas K, Jiang L, Bloom J, Spooner E, Maier M, Bitan G, Lemere CA. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice.. Neurobiology of aging, 2006.
  102. Baumketner A, Bernstein SL, Wyttenbach T, Bitan G, Teplow DB, Bowers MT, Shea JE. Amyloid beta-protein monomer structure: a computational and experimental study.. Protein science : a publication of the Protein Society, 2006.
  103. Bitan G. Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins.. Methods in enzymology, 2006.
  104. Fradinger EA, Bitan G. En route to early diagnosis of Alzheimer's disease--are we there yet?. Trends in biotechnology, 2005.
  105. Bitan G, Fradinger EA, Spring SM, Teplow DB. Neurotoxic protein oligomers--what you see is not always what you get.. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2005.
  106. Bernstein SL, Wyttenbach T, Baumketner A, Shea JE, Bitan G, Teplow DB, Bowers MT. Amyloid beta-protein: monomer structure and early aggregation states of Abeta42 and its Pro19 alloform.. Journal of the American Chemical Society, 2005.
  107. Vollers SS, Teplow DB, Bitan G. Determination of Peptide oligomerization state using rapid photochemical crosslinking.. Methods in molecular biology (Clifton, N.J.), 2005.
  108. Bitan G, Teplow DB. Preparation of aggregate-free, low molecular weight amyloid-beta for assembly and toxicity assays.. Methods in molecular biology (Clifton, N.J.), 2005.
  109. Urbanc B, Cruz L, Yun S, Buldyrev SV, Bitan G, Teplow DB, Stanley HE. In silico study of amyloid beta-protein folding and oligomerization.. Proceedings of the National Academy of Sciences of the United States of America, 2004.
  110. Bitan G, Teplow DB. Rapid photochemical cross-linking--a new tool for studies of metastable, amyloidogenic protein assemblies.. Accounts of chemical research, 2004.
  111. Bitan G, Tarus B, Vollers SS, Lashuel HA, Condron MM, Straub JE, Teplow DB. A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization.. Journal of the American Chemical Society, 2003.
  112. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease.. The Journal of clinical investigation, 2003.
  113. Bitan G, Vollers SS, Teplow DB. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization.. The Journal of biological chemistry, 2003.
  114. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways.. Proceedings of the National Academy of Sciences of the United States of America, 2002.
  115. Sun B, Fan W, Balciunas A, Cooper JK, Bitan G, Steavenson S, Denis PE, Young Y, Adler B, Daugherty L, Manoukian R, Elliott G, Shen W, Talvenheimo J, Teplow DB, Haniu M, Haldankar R, Wypych J, Ross CA, Citron M, Richards WG. Polyglutamine repeat length-dependent proteolysis of huntingtin.. Neurobiology of disease, 2002.
  116. Kirkitadze MD, Bitan G, Teplow DB. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies.. Journal of neuroscience research, 2002.
  117. Scheibler L, Mierke DF, Bitan G, Rosenblatt M, Chorev M. Identification of a contact domain between echistatin and the integrin alpha(v)beta(3) by photoaffinity cross-linking.. Biochemistry, 2001.
  118. Bitan G, Lomakin A, Teplow DB. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins.. The Journal of biological chemistry, 2001.
  119. Inbar O, Liefshitz B, Bitan G, Kupiec M. The relationship between homology length and crossing over during the repair of a broken chromosome.. The Journal of biological chemistry, 2000.
  120. Bitan G, Scheibler L, Mierke DF, Rosenblatt M, Chorev M. Ligand-integrin alpha v beta 3 interaction determined by photoaffinity cross-linking: a challenge to the prevailing model.. Biochemistry, 2000.
  121. Bitan G, Scheibler L, Teng H, Rosenblatt M, Chorev M. Design and evaluation of benzophenone-containing conformationally constrained ligands as tools for photoaffinity scanning of the integrin alphaVbeta3-ligand bimolecular interaction.. The journal of peptide research : official journal of the American Peptide Society, 2000.
  122. Behar V, Bisello A, Bitan G, Rosenblatt M, Chorev M. Photoaffinity cross-linking identifies differences in the interactions of an agonist and an antagonist with the parathyroid hormone/parathyroid hormone-related protein receptor.. The Journal of biological chemistry, 2000.
  123. Bitan G, Scheibler L, Greenberg Z, Rosenblatt M, Chorev M. Mapping the integrin alpha V beta 3-ligand interface by photoaffinity cross-linking.. Biochemistry, 1999.
  124. Bitan G, Sukhotinsky I, Mashriki Y, Hanani M, Selinger Z, Gilon C. Synthesis and biological activity of novel backbone-bicyclic substance-P analogs containing lactam and disulfide bridges.. The journal of peptide research : official journal of the American Peptide Society, 1997.
  125. Behrens S, Mathä B, Bitan G, Gilon C, Kessler H. Structure-activity relationship of the ring portion in backbone-cyclic C-terminal hexapeptide analogs of substance P. NMR and molecular dynamics.. International journal of peptide and protein research, 1996.
  126. Byk G, Halle D, Zeltser I, Bitan G, Selinger Z, Gilon C. Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P.. Journal of medicinal chemistry, 1996.
  127. Bitan G, Zeltser I, Byk G, Halle D, Mashriki Y, Gluhov EV, Sukhotinsky I, Hanani M, Selinger Z, Gilon C. Backbone cyclization of the C-terminal part of substance P. Part 1: The important role of the sulphur in position 11.. Journal of peptide science : an official publication of the European Peptide Society, 1996.